Company Description: Farcast's mission is to improve predictability in cancer treatment. Farcast's Human Tumor Microdynamics (hTMD) platform generates and mines“tumor response big data” by uniquely culturing and assaying fresh cancer tissue samples. Farcast's platform delivers truly “biorepresentative level 3” response insights and AI driven biosignatures discovery The platform has the experience of processing over 24,000 live human tumors processed Farast is a revenue stage company with 10 biotech customers across the US, Europe, Japan for therapeutics development services Farcast is in "pre-revenue" stage in developing a diagnostic test technology and there are 3 concurrent ongoing trials that are aimed at delivering clinical convergence.